In summary, increased levels of p16 promoted exhaustion of tumor-infiltrating CD8+ T cells, leading to a reduction in the effectiveness of ACT immunotherapy, while p16 knockout blocked T cell terminal exhaustion and facilitated its persistence in vivo. This evidence concerns the gene CD8A and neoplasm.